Published June 10, 2026 | Version v1
Dataset Open

DAVOLASHGA CHIDAMLI DEPRESSIYANI DAVOLASHDA NEYROMEDIATOR TIZIMLARI: KETAMIN VA PSIXODELIKLARNING GLUTAMAT HAMDA SEROTONIN (5-HT2A) TIZIMLARIGA TA'SIRI

Authors/Creators

  • 1. Toshkent KIUT xalqaro unversiteti Namangan filiali

Description

Ushbu maqolada davolashga chidamli depressiyani davolashda neyromediator tizimlarining roli zamonaviy nuqtai nazardan tahlil qilingan. An’anaviy monoaminli antidepressantlarning cheklovlari hamda depressiya patofiziologiyasida glutamatergik va serotonergik tizimlarning ahamiyati ko‘rib chiqilgan. Ketamin — N-metil-D-aspartat (NMDA) retseptorlari antagonisti bo‘lib, glutamat to‘lqini, AMPA retseptorlari faollashuvi va BDNF/mTOR yo‘li orqali sinaptogenezni rag‘batlantirib, tez ta’sir etuvchi antidepressant samara beradi; uning S-enantiomeri eskinetamin 2019-yilda davolashga chidamli depressiya uchun tasdiqlangan. Psilotsibin esa serotonin 5-HT2A retseptorlari agonisti sifatida glutamat ajralishini kuchaytirib, neyroplastiklikni oshiradi. Klinik sinovlar istiqbolli natijalar bergan bo‘lsa-da, psixodeliklar hali tadqiqot bosqichida bo‘lib, faqat nazorat ostidagi klinik sharoitda qo‘llaniladi.

Files

441-445.pdf

Files (155.2 kB)

Name Size
md5:ca2f4173dd549f54170b4a8716e80c69
155.2 kB Preview Download

Additional details

References

  • 1.Berman R.M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients // Biological Psychiatry. 2000. Vol. 47, No. 4. P. 351-354.
  • 2.Zarate C.A. Jr, Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression // Archives of General Psychiatry. 2006. Vol. 63, No. 8. P. 856-864.
  • 3.Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets // Science. 2012. Vol. 338, No. 6103. P. 68-72.
  • 4.Zanos P., Gould T.D. Mechanisms of ketamine action as an antidepressant // Molecular Psychiatry. 2018. Vol. 23, No. 4. P. 801-811.
  • 5.Popova V., Daly E.J., Trivedi M., et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression // American Journal of Psychiatry. 2019. Vol. 176, No. 6. P. 428-438.